The results showed that the exacerbation of lipid metabolic disorders caused by MT1B silencing in HepG2 and AML12 cells could be rescued by treatment with AKT inhibitor (Fig. 5A–C and Supplementary Fig. S4A–C). Here, AKT1 is linked to Disorder of lipid metabolism.